종목/AVR
Anteris Technologies Global Corp.
예정된 실적 발표가 아직 잡히지 않았습니다.
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
| 발표일 | 분기 | EPS 예상 | EPS 실제 | Surprise | 매출 실제 | 발표 직후 반응 |
|---|---|---|---|---|---|---|
| 5월 12일 (화) | 2026 Q1 | $-0.16 | — | — | — | — |
| 5월 11일 (월) | 2026 Q1 | $-0.16 | — | — | — | — |
| UNH | 유나이티드헬스 | 345B | +8.9% | 75% (3/4) |
| MRK | 머크 | 275B | +16.0% | 100% (4/4) |